Ananda Pharma Plc (AQU:ANA)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2750
0.00 (0.00%)
At close: Oct 20, 2025
Market Cap10.75M
Revenue (ttm)62.00
Net Income (ttm)-3.77M
Shares Out4.30B
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Openn/a
Previous Close0.2750
Day's Rangen/a
52-Week Range0.2500 - 0.5350
Beta0.43
RSI15.88
Earnings DateOct 29, 2025

About Ananda Pharma

Ananda Pharma Plc, along with its subsidiaries, operate as a biopharmaceutical company that develops cannabidiol-based medicine to treat endometriosis and chemotherapy-induced peripheral neuropathy chronic conditions across the United Kingdom and internationally. Its lead product, MRX1, is in Phase 2a feasibility trials for endometriosis-related pain and in a Phase 2 efficacy study to investigate chemotherapy-induced peripheral neuropathy. The company also offers MRX2 and MRX2t, which are cannabinoid-based medicines in Phase 3 clinical trials f... [Read more]

Industry Pharmaceutical Preparations
Founded 2018
Employees 9
Stock Exchange Aquis Exchange
Ticker Symbol ANA
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.